NASDAQ: NRXP - NRx Pharmaceuticals, Inc.

Lønnsomhet i seks måneder: +55.73%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan NRx Pharmaceuticals, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2017-12-04
ISIN US6294441000
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.nrxpharma.com
Цена ао 2.07
Prisendring per dag: -2.96% (2.03)
Prisendring per uke: +10.67% (1.78)
Prisendring per måned: -3.9% (2.05)
Prisendring over 3 måneder: -56.12% (4.49)
Prisendring over seks måneder: +55.73% (1.265)
Prisendring per år: -52.87% (4.18)
Prisendring over 3 år: -10.45% (2.2)
Prisendring over 5 år: -81.15% (10.45)
Prisendring siden begynnelsen av året: +64.17% (1.2)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV -0.6929 0
P/E 0 0
EV/EBITDA -1.15 0
Total: 2.5

Effektivitet

Navn Betydning Karakter
ROA, % -458.25 0
ROE, % 143.76 10
Total: 3.33

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.3555 10
Total: 9.4

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % -64 0
Lønnsomhet EPS, % 563.05 10
Total: 6
Flere detaljer

Institusjoner Volum Dele, %
Vanguard Group Inc 144518 0.15
AdvisorShares Investments, LLC 64263 0.07
Geode Capital Management, LLC 41192 0.04
Blackrock Inc. 29071 0.03
Renaissance Technologies, LLC 20048 0.02
Royal Bank of Canada 15021 0.02
One Wealth Management Investment & Advisory Services, LLC 14040 0.01
Bridgeway Capital Management, Inc. 12270 0.01
State Street Corporation 11424 0.01
Northern Trust Corporation 7500 0.01



Veileder Stillingstittel Betaling Fødselsår
Mr. Stephen H. Willard Esq. Acting Corporate Secretary, CEO & Director 500k 1961 (64 år)
Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chief Scientist Officer & Chairman 630.2k 1957 (68 år)
Dr. Riccardo Panicucci Ph.D. Chief Manufacturing & Technology Officer 240k 1961 (64 år)
Mr. Richard Clavano Narido CFO & Treasurer 255.01k 1979 (46 år)
Suzanne Messere Investor Relations N/A
Dr. Philip T. Lavin Ph.D. Chief Methodologist N/A 1947 (78 år)
Mr. Matthew Patrick Duffy Chief Business Officer N/A 1963 (62 år)

Adresse: United States, Wilmington. DE, 1201 Orange Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.nrxpharma.com